Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: NetraMark Holdings Inc.

Market Cap 73.27M 51.74M 45.21M 41.82M 39.03M 4.89B 73.81M 497M 193M 2.4B 194M 190M 8.35B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 73.27M 51.74M 45.21M 41.82M 39.03M 4.89B 73.81M 497M 193M 2.4B 194M 190M 8.35B EV / Sales 2026 *
183x
EV / Sales 2027 * -
Free-Float
87.53%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer - 16/02/2022
President - 03/07/2022
Director of Finance/CFO 57 17/07/2022
Director TitleAgeSince
Chairman 40 08/06/2025
Director/Board Member - -
Director/Board Member - 15/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-3.77% - - 51.74M
+1.58%-5.33%-23.29%+11.28% 2,729B
-0.72%-11.09%-15.33%+744.40% 286B
-3.02%+5.84%+266.81%+811.49% 135B
-2.00%-1.75%+29.80%+69.12% 107B
+1.38%+5.01%-0.03%+12.22% 88.96B
+0.49%-4.11%+71.10%+136.59% 78.8B
+1.79%+4.22%-41.07%+53.58% 54.54B
+2.59%+6.77%+1.64%+73.10% 44.48B
+2.82%-1.29%-52.94%+28.68% 33.84B
Average +0.45%+0.18%+26.30%+215.61% 395.37B
Weighted average by Cap. +1.07%-6.71%-7.60%+106.83%

Financials

2026 *2027 *
Net sales 401K 283K 247K 229K 214K 26.75M 404K 2.72M 1.06M 13.15M 1.06M 1.04M 45.69M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!